Entering text into the input field will update the search result below

Evotec unit nabs $18.2M grant to develop antibodies against COVID-19

Jul. 22, 2020 3:16 AM ETEvotec SE (EVOTF) StockEVOBy: SA News Team
  • The U.S. Department of Defense ("DoD") has awarded Evotec's (OTCPK:EVOTF) Seattle-based unit, Just - Evotec Biologics, a contract valued up to $18.2M to develop and manufacture monoclonal antibodies ("mAbs") for treatment and/or prevention of COVID-19.
  • The goal of this programme is to rapidly and efficiently deliver the mAbs to the DOD.
  • Under the contract, Just - Evotec Biologics will design a highly efficient manufacturing process for the production of Current Good Manufacturing Practice (cGMP) clinical supplies of two monoclonal antibodies.
  • The mAbs will be tested in early-stage clinical trials and ultimately used for COVID-19 infections.

Recommended For You

More Trending News

About EVOTF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EVOTF--
Evotec SE